PD-1/PD-L1 inhibitors represent a highly promising cancer treatment option because, by blocking PD-1–PD-L1 signaling, they can prevent tumor immune escape and facilitate a positive immune response to kill tumor cells. This evidence concerns the gene CD274 and neoplasm.